Everest Group has recognised Indegene as a front-runner in generative AI (GenAI) life sciences market adoption.

In its report, 'AI-deas to Action: Operationalizing Generative AI in Life Sciences', Everest Group acknowledged Indegene’s comprehensive GenAI capabilities, including scale, breadth of use cases, strategic partnerships and value delivered to clients.

The report highlights how Indegene’s holistic GenAI strategy and enterprise-grade, production-ready solutions are helping life sciences companies streamline operations and realize strong productivity improvements across several use cases, spanning the clinical, medical and commercial elements of the life sciences value chain.

“We believe GenAI is a generational opportunity for life sciences leaders to make the strategic leap and drive transformational business impact. And we are helping them make the most of GenAI's potential - solve real business challenges, prioritize use cases that deliver clear business outcomes, and realize benefits in a responsible and compliant way”, said Tarun Mathur, CTO, Indegene.

“This recognition by the Everest Group reinforces our commitment to contextualizing GenAI for some of the most challenging use cases, and help leaders tackle them with fit-for-purpose solutions,” added Mathur.

Everest Group assessed each service provider’s GenAI capabilities on 4 specific parameters: scale, with a focus on revenue, client reach and pipeline; the quality and impact of industry-specific use cases across the value chain either in pilot or production stages; the kind of strategic partnerships across the board and the capability boost thereof; and the quantum of real, measurable value realized by clients.